CNB Financial Q4 EPS $0.80 Up From $0.40 YoY

CNB Financial (NASDAQ:CCNE) reported quarterly earnings of $0.80 per share. This is a 100 percent increase over earnings of $0.40 per share from the same period last year.

byBill Haddad

January 24, 2022

1 minute read

CNB Financial (NASDAQ:CCNE) reported quarterly earnings of $0.80 per share. This is a 100 percent increase over earnings of $0.40 per share from the same period last year.

Ethereum Sees $102M Liquidations, Bitcoin And Dogecoin Trade Sideways

By Samyuktha Sriram

Today, 8:52 PM

Ethereum (CRYPTO: ETH) led cryptocurrency liquidations by a large margin, with $102 million liquidated over the last 24 hours.

$DOGE

Boeing And American Express Lead The DIA Sharply Lower Monday

By Henry Khederian

Today, 8:52 PM

U.S. indices were trading lower Monday amid renewed COVID-19 concerns, which have weighed on reopening stocks and clouded recovery outlook. The U.S. is also expected to blame China on cyberattacks earlier in the year, which has added to macro uncertainty.

AXP

Events
News

AstraZeneca Announced TAGRISSO (osimertinib) Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients with EGFR-mutated Lung Cancer; Data Presented at ESMO 2022

By Charles Gross

Today, 8:52 PM

TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years

AZN

Earnings

Camden National’s Earnings Outlook

By Benzinga Insights

Today, 8:52 PM

Camden National (NASDAQ:CAC) unveils its next round of earnings this Tuesday, July 27. Here is Benzinga's everything-that-matters guide for the earnings announcement.

CAC

CNB Financial Q4 EPS $0.80 Up From $0.40 YoY

Related Posts

Ethereum Sees $102M Liquidations, Bitcoin And Dogecoin Trade Sideways

Boeing And American Express Lead The DIA Sharply Lower Monday

AstraZeneca Announced TAGRISSO (osimertinib) Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients with EGFR-mutated Lung Cancer; Data Presented at ESMO 2022

Camden National’s Earnings Outlook